ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extensionLaura M. Gault, Weining Robieson, Ahmed A. Othman et al.|Alzheimer s Research & Therapy|2016Cited by 39
Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer DiseaseRobert Lenz, Mario Saltarelli, Yili Pritchett et al.|Alzheimer Disease & Associated Disorders|2015Cited by 28